The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Assessing social determinants of health and optimizing resource support for patients with metastatic breast cancer: Results from the LIFT-UP study.
 
Temidayo Fadelu
Research Funding - Celgene (Inst); Cepheid (Inst)
 
Melissa E. Hughes
No Relationships to Disclose
 
Molly Skeffington
No Relationships to Disclose
 
Alyssa R. Martin
No Relationships to Disclose
 
Renee Fullem
No Relationships to Disclose
 
Adriana Perilla Glen
No Relationships to Disclose
 
Sandra Brown
No Relationships to Disclose
 
Ross J Kusmick
No Relationships to Disclose
 
Abigail Moore
No Relationships to Disclose
 
Simone Buck
No Relationships to Disclose
 
Kerry Sendrick
No Relationships to Disclose
 
Caitlin Caporale
Employment - Dana Farber Cancer Hospital; Foundation Medicine
(OPTIONAL) Uncompensated Relationships - City of Hope
 
Sarah L Sammons
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo; Foundation Medicine; Loxo/Lilly; Novartis; Pfizer; Relay Therapeutics; Sermonix Pharmaceuticals
Research Funding - AstraZeneca/MedImmune (Inst); Lilly (Inst); Relay Therapeutics (Inst); Relay Therapeutics (Inst); Seagen (Inst); Sermonix Pharmaceuticals (Inst)
 
Sara M. Tolaney
Consulting or Advisory Role - AADi; ARC Therapeutics; Artios Biopharmaceuticals; AstraZeneca; Bayer; BeyondSpring Pharmaceuticals; Blueprint Medicines; Bristol-Myers Squibb; CytomX Therapeutics; Daiichi Sankyo; eFFECTOR Therapeutics; Eisai; Genentech; Hengrui Pharmaceutical (USA); Immunomedics/Gilead; Incyte; Infinity Pharmaceuticals; Jazz Pharmaceuticals; Lilly; Menarini Group; Merck; Natera; Novartis; OncXerna Therapeutics; Pfizer; Reveal Genomics; Sanofi; Seagen; Sumitovant Biopharma; Systimmune; Tango Therapeutics; Umoja Biopharma; Zentalis; Zetagen; Zymeworks
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Exelixis (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); Lilly (Inst); Merck (Inst); NanoString Technologies (Inst); Novartis (Inst); OncoPep (Inst); Pfizer (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - Gilead Sciences; Lilly; Sanofi
 
Nancy U. Lin
Stock and Other Ownership Interests - Artera
Consulting or Advisory Role - Artera; AstraZeneca; Blueprint Medicines; Daiichi Sankyo; Eisai; Johnson & Johnson/Janssen; Menarini; Olema Pharmaceuticals; Pfizer; Seagen
Research Funding - Genentech (Inst); Merck (Inst); Olema Pharmaceuticals (Inst); Pfizer (Inst); Seagen (Inst); Zion Pharma (Inst)
Patents, Royalties, Other Intellectual Property - Royalties for chapter in Up-to-Date regarding management of breast cancer brain metastases; Royalties, Jones & Bartlett
Travel, Accommodations, Expenses - Olema Pharmaceuticals
 
Rachel A. Freedman
Employment - Firefly Health (I)
Stock and Other Ownership Interests - Firefly Health (I)
Research Funding - Eisai (Inst); Genentech/Roche (Inst); Puma Biotechnology (Inst)